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Dysregulation of the astroglial glutamate transporters GLAST and GLT-1 has
been implicated in several neurodegenerative disorders, including amyotrophic
lateral sclerosis (ALS) where a loss of GLT-1 protein expression and activity
is reported. Furthermore, the two principal C-terminal splice variants of GLT-1
(namely GLT-1a and GLT-1b) show altered expression ratio in animal models
of this disease. Considering the putative link between inflammation and
excitotoxicity, we have here characterized the influence of TNF-α on glutamate
transporters in cerebral cortical astrocyte cultures from wild-type rats and from a
rat model of ALS (hSOD1G93A). Contrasting with the down-regulation of GLAST,
a 72 h treatment with TNF-α substantially increased the expression of GLT-1a
and GLT-1b in both astrocyte cultures. However, as the basal level of GLT-1a
appeared considerably lower in hSOD1G93A astrocytes, its up-regulation by
TNF-α was insufficient to recapitulate the expression observed in wild...
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Abstract
Dysregulation of the astroglial glutamate transporters GLAST and GLT-1 has been implicated in several neurodegenerative
disorders, including amyotrophic lateral sclerosis (ALS) where a loss of GLT-1 protein expression and activity is reported.
Furthermore, the two principal C-terminal splice variants of GLT-1 (namely GLT-1a and GLT-1b) show altered expression
ratio in animal models of this disease. Considering the putative link between inflammation and excitotoxicity, we have here
characterized the influence of TNF-a on glutamate transporters in cerebral cortical astrocyte cultures from wild-type rats
and from a rat model of ALS (hSOD1G93A). Contrasting with the down-regulation of GLAST, a 72 h treatment with TNF-a
substantially increased the expression of GLT-1a and GLT-1b in both astrocyte cultures. However, as the basal level of GLT-
1a appeared considerably lower in hSOD1G93A astrocytes, its up-regulation by TNF-a was insufficient to recapitulate the
expression observed in wild-type astrocytes. Also the glutamate uptake activity after TNF-a treatment was lower for
hSOD1G93A astrocytes as compared to wild-type astrocytes. In the presence of the protein synthesis inhibitor cycloheximide,
TNF-a did not influence GLT-1 isoform expression, suggesting an active role of dynamically regulated protein partners in the
adaptation of astrocytes to the inflammatory environment. Confirming the influence of inflammation on the control of
glutamate transmission by astrocytes, these results shed light on the regulation of glutamate transporter isoforms in
neurodegenerative disorders.
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Introduction
Disturbances in glutamate homeostasis, which lead to toxic
accumulation of this excitatory neurotransmitter in the synaptic
cleft, are observed in several neuropathologies. Indeed, excessive
activation of ionotropic glutamate receptors is commonly associ-
ated with irreversible excitotoxic damages to neuronal cells [1].
Specific high-affinity transporters contribute to the rapid and
efficient clearance of glutamate by which the nervous parenchyma
is protected against the extracellular accumulation of glutamate.
Among the five subtypes of glutamate transporters identified in
cells of the nervous parenchyma, the astroglial glutamate
transporters GLAST (the rodent homologue of human EAAT1)
and GLT-1 (EAAT2) [2] are best characterized as they likely
ensure most of the glutamate uptake in physiological conditions.
Hence, dysfunction of these two glutamate transporters is clearly
implicated in neurodegenerative insults, in particular amyotrophic
lateral sclerosis (ALS) [3,4], a fatal disease characterized by the
progressive and specific loss of motor neurons that has been
correlated with deficient GLT-1 expression and activity [5,6]. The
subsequent identification of splice variants of this transporter was
followed by the demonstration of distinct regulatory profiles for the
most abundant isoforms, namely GLT-1a and GLT-1b [7,8].
Differences in the regulation of these splice variants could indeed
explain their altered expression ratio in pathological contexts,
including ALS [9–11]. It is, however, noteworthy that so far, the
majority of biochemical studies failed to distinguish between these
two isoforms or essentially focused on GLT-1a because the
distinctive roles of each of these isoforms and their physiological
relevance remain poorly understood.
A key pathological feature of ALS in both human and animal
models is the extensive astrocytic activation and microgliosis which
accompanies the release of inflammatory mediators [12,13].
Hence, excitotoxicity and neuroinflammation are concomitant in
various neuropathologies such as Parkinson disease, multiple
sclerosis, Alzheimer disease or ALS [3,14]. Indeed, the expression
and activity of glutamate transporters are influenced by cytokines,
growth factors and reactive oxygen species (ROS), common
mediators of neuroinflammation [15]. In this study, we aimed at
comparing the influence of an inflammatory environment on the
glutamate transporters GLAST, GLT-1a and GLT-1b, in primary
cultures of cortical astrocytes derived from wild-type or transgenic
rats carrying a mutated form of the human superoxide dismutase 1
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e97649
(hSOD1G93A). These rodents recapitulate the symptoms and
biochemical features of ALS and the strain constitutes a validated
model of the disease even though the hSOD1G93A expression was
so far never validated in primary cultures of astrocytes. Mimicking
the inflammation detected in the nervous tissues of ALS rats
[16,17], the cell cultures were exposed to tumor necrosis factor a
(TNF-a), a pro-inflammatory cytokine for which glial cells from
this transgenic rat strain show increased immune reactivity
[16,18].
Materials and Methods
Animals and Ethics Statement
All experiments were conducted on samples collected from
Sprague-Dawley rats maintained in strict adherence to the EU
directive of 22/09/2010 (2010/63/EU). The ethical committee of
the Universite´ catholique de Louvain for animal experiments
specifically approved this study, which received the agreement nu
2010/UCL/MD/032. Our laboratory received agreement num-
ber LA 1230297 from the Ministry of Agriculture. All animals
were housed in cages that provided an environment with
controlled light/dark cycles, temperature and humidity. Every
effort was made to minimize suffering during the manipulations
and rats were euthanized with CO2, except for pups that were
sacrificed by decapitation. Rats carrying the hSOD1G93A trans-
gene were initially obtained from Dr. R. Pochet (Universite´ Libre
de Bruxelles, Belgium). These rats were genotyped after birth with
genomic DNA extracted from a tail biopsy using PCR as
previously described [11].
Tissue Dissection
To measure the expression of the endogenous (rSOD1) and
exogenous (hSOD1) SOD1 in mutant rats, wild-type and
hSOD1G93A males were sacrificed at various stages of the disease
to collect the lumbar spinal cord or the cortex. The weight and the
motor score of each animal developing ALS disease were
evaluated as previously described by Matsumoto [19]. At various
stages of the disease (at postnatal day (P) 5, the non-paralysed
stages P60 and P120, first signs of paralysis P150, and end-stage of
the disease P195 corresponding to the motor score 0), rats were
euthanized with CO2 (except at P5; here decapitation was used)
and the lumbar spinal cord was collected and the meninges were
removed. Tissues were immediately frozen in liquid nitrogen and
stored at 280uC until use.
Astroglial Culture and Treatments
Primary cultures from the cortex of either wild-type or
transgenic hSOD1G93A rats pups (P4–5) were performed imme-
diately after genotyping. Cerebral cortices of these pups were
collected and meninges were carefully removed and kept in Petri
dishes containing a solution of PBS/2% glucose. Tissues were then
suspended in PBS/glucose supplemented with 10 mg/mL trypsin
(Worthington, United States), 1 mg/mL DNase (Worthington),
5 mg/mL MgSO4 (Sigma-Aldrich, Diegem, Belgium) at 37uC for
3 min and washed with PBS/glucose. Tissues were mechanically
dissociated in Dulbecco’s Modified Eagle Medium (DMEM, Life
Technologies, Gent, Belgium) containing 0.5 mg/mL DNase.
After a centrifugation of 5 min at 1200 g, cells were suspended in
DMEM containing 4.5 g/L glucose, 25 mmol/L HEPES and
supplemented with 10% fetal bovine serum (FBS, Thermoscien-
tific, Tournai, Belgium), 100 units/mL penicillin, 100 mg/mL
streptomycin and 6 mmol/L glutamine (Life Technologies) and
aggregates were removed by filtration using a strainer with a pore
size of 100 mm. Isolated cells were then incubated for growing at
37uC in a humidified atmosphere containing 5% CO2 into 175
cm2 culture flasks and culture medium was renewed after one
week. Non astroglial cells such as microglia and oligodendrocytes
were removed after 10 days by 24 h shaking at 200 rpm on an
orbital shaker. After two weeks of proliferation, cells were collected
by trypsinisation (trypsin-EDTA 0.05%, Life Technologies) and
plated at 104 cells/cm2. Cells were seeded into non-coated 6-well
plates for quantitative PCR measurements and Western blotting,
or were distributed on poly-L-lysine coated 12-well plates for D-
[3H]-aspartate uptake measurement. After 48 h, cells were fed
with new culture medium containing 3% of FBS during 4 days.
Then, astrocyte treatment with TNF-a (20 ng/mL, AbD Serotec,
Oxford, England) in the same medium was commenced and lasted
72 h; alternatively, astrocytes were incubated for 48 h with
cycloheximide (10 mg/mL, Sigma Aldrich), supplemented or not
with 20 ng/mL TNF-a.
RNA Extraction, Reverse Transcription and Quantitative
PCR Measurements
Total RNA extraction from cells was carried out using the
Tripure Isolation Reagent (Roche Diagnostic, Mannheim Ger-
many) following the manufacturer’s protocol. Samples were
treated with RQ1 RNase-free DNase kit (Promega Benelux,
Leiden, The Netherlands) to remove DNA contamination before
cDNA synthesis. Reverse transcription and quantitative PCR were
performed as previously detailed [11]. Amplification of each target
transcript with appropriates primers (Table 1, Life Technologies)
was performed in the same conditions with serial dilutions of a
cloned fragment of the corresponding transporter cDNA se-
quence. Each sample was normalized with the relative expression
of GAPDH and TATA binding protein (TBP). Thereby,
quantification of GLT-1a, GLT-1b and GLAST was carried out
using plasmids expressing one or the other transcript as internal
control and reported as cDNA copy number per mg of total RNA.
Western Blotting
Astrocytes seeded in 6-well plates were rinsed with PBS and
scraped in ice-cold lysis buffer (Tris 10 mM, pH 7.4, ethylene
diamine tetraacetic acid 1 mM, ethylene glycol tetraacetic acid
10 mM, DL-dithiotreitol (DTT) 2 mM, Igepal-NP40 1%, glycerol
20%) while lumbar spinal cord and cortex tissue previously
dissected were homogenized in the same lysis buffer using a
prechilled Teflon/glass homogenizer. Samples were then centri-
fuged (1000 g, 3 min) to remove insoluble material and sonicated.
Protein concentration was determined by Lowry method, using
DC Protein Assay Reagents Package (BioRad Laboratories) and
samples were diluted in loading buffer (Tris 125 mM pH 6.8,
glycerol 20%, sodium dodecyl sulfate (SDS) 4% and bromophenol
blue 0.01%) and boiled for 5 min. Samples were electrophoresed
through a 10% or a 14% (for SOD1) SDS-PAGE and transferred
to nitrocellulose membrane by electroblotting. Membrane were
incubated 30 min in Tris-buffered saline (TBS-Tris 50 mM
pH 7.4, NaCl 150 mM) containing 0.05% Tween-20 and 5%
non-fat milk to reduce non-specific labeling. Immunoprobing was
carried out by incubating membranes overnight at 4uC with
primary antibodies recognizing GLT-1a (guinea pig polyclonal
antibody used at 1:2500, Millipore, Brussels, Belgium), GLT-1b
(rat monoclonal antibody, 1:1500, previously characterized in our
laboratory [7]), GLAST (goat polyclonal antibody, 1:3000, Santa
Cruz Biotechnology, Heildelberg, Germany) hSOD1/rSOD1
(rabbit polyclonal antibody, 1:2000, LF-PA0013, AbFrontier -
Gentaur Molecular Products BVBA, Belgium) and GAPDH
(rabbit polyclonal antibody, 1:30 000, Sigma Aldrich). Membrane
were then incubated 1 h at 22uC with peroxidase-conjugated
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secondary antibody, goat anti-guinea pig IgG (1:5000, Sigma),
mouse monoclonal anti-rat IgG (1:4000, Laboratory of Experi-
mental Surgery, UCL, Belgium), rabbit anti-goat IgG (1:2000,
Sigma) and goat anti-rabbit IgG (1:3000, Sigma), respectively.
Immunoreactive proteins were detected with enhanced chemilu-
minescence reagent (Perkin Elmer NEN, Zaventem, Belgium)
followed by autoradiography. Densitometric analysis of the signal
was performed using ImageJ (Broken Symmetry Software). Of
note, while picture depicting the immunoblots were rearranged for
display in some figures, samples from WT and hSOD1G93A rats
were systematically run on the same gel allowing for comparison of
the immunoreactive signals.
D-[3H]-aspartate Uptake Measurement
Glutamate transporters activity was evaluated by uptake assays
using D-aspartate, a transportable analogue of L-glutamate, which
is not metabolized and does not interact with glutamate receptors.
At the end of treatment with TNF-a, plates were placed at the
surface of a 37uC water bath. Cells were rinsed three times with
Krebs buffer (25 mmol/L HEPES, 4.8 mmol/L KCl, 1.2 mmol/
L KH2PO4, 1.3 mmol/L CaCl2, 1.2 mmol/L MgSO4, 6 mmol/L
glucose and 140 mmol/L NaCl, pH 7.4). D-[3H]-aspartate
(50 nmol/L, specific activity of 11.3 Ci/mmol, Perkin Elmer)
was added on the cells in presence or not of the appropriate
inhibitors of glutamate transporters. Inhibitors of GLT-1 (WAY-
213613, Tocris, Bristol, UK) and GLAST (UCPH-101, Tocris)
were used at 100 and 10 mmol/L, respectively. After 6 min,
uptake was stopped by three rinses with cold Krebs buffer (NaCl
replaced by choline chloride) and cells were lysed with NaOH
0.1 N. Radioactivity was measured using the liquid scintillation
solution Microscint 40 and the TopCount NXT Microplate
Scintillation and Luminescence Counter (Perkin Elmer). A fraction
of the lysate was used for protein determination by Bradford
method using BioRad Protein Assay Dye Reagent (BioRad).
Glutamate uptake rate was expressed as picomole of D-[3H]-
aspartate transported per minute and per milligram of protein.
Statistical Analyses
Statistical analyses were performed with GraphPad Prism
version 5.03 (GraphPad software, San Diego, CA, USA). Data
were expressed as means with standard error of the mean (SEM)
and results were analyzed by two-way ANOVA followed by a
Bonferroni post-hoc test. Values of p,0.05 were considered as
statistically significant.
Results
Expression of hSOD1 in Cultured Astrocytes from
hSOD1G93A Rats
The ALS model overexpressing hSOD1G93A is abundantly used
to examine the molecular mechanisms underlying the disease.
During aging, transgenic animals develop typical features of the
disease and this is correlated with the progressive accumulation of
the mutated SOD1 protein in the cytoplasm of both neurons and
glial cells [20,21]. While cortical astrocyte cultures derived from
newborn rodents are widely used to study specific astrocytic
alteration associated with diverse insults, the expression of the
human mutated form of SOD1 has never been characterized in
cultures derived from hSOD1G93A rat pups. Herein, we therefore
investigated the expression of SOD1 in cortical astrocytes. The
human and rat SOD1 are recognized by the same antibody but
they show different molecular weights and can be distinguished
after SDS-PAGE and Western blotting. Our data shown in
Figure 1A clearly evidence the expression of hSOD1 in cultured
cortical astrocytes from hSOD1G93A rodents. As expected, the
rSOD1 protein was detected in astrocytes from both wild-type and
transgenic rats, even though the signal corresponding to this
endogenous protein is considerably lower as compared to the
human protein in the hSOD1G93A samples. These results
appeared similar with those depicting the expression of SOD1 in
the lumbar spinal cord of hSOD1G93A rats in which a high
expression of the hSOD1 is already detected at P5 (Fig. 1B). In the
cortex, expression of the human protein was actually low at early
stages, but increased with aging (Fig. 1C). This suggests that
in vitro maturation of cortical astrocytes promotes the expression
of the transgene and that these cells constitute a validated model to
study the influence of hSOD1G93A in astrocytes.
TNF-a Down-regulates the mRNA and Protein Expression
of GLAST in Wild-type and hSOD1G93A Astrocytes
In absence of treatment with TNF-a, the level of GLAST
transcript tends to be lower in transgenic astrocytes as compared
to wild-type cells, but we failed to measure any statistical
significance for this observation. The addition of TNF-a for
72 h induced a clear down-regulation of the GLAST mRNAs in
wild-type astrocytes, reaching a 50% decrease in comparison with
the control condition and a trend of decrease in hSOD1G93A
cultures (Fig. 2A). Besides, the cytokine strongly reduced the level
of GLAST proteins (at least 50% of reduction in comparison with
control conditions) both in wild-type and ALS cultured astrocytes,
correlating with the effects observed at the mRNA level (Fig. 2B).
TNF-a Up-regulates the mRNA and Protein Expression of
GLT-1a and GLT-1b Splice Variants
The influence of inflammatory stimuli on GLT-1 was previously
examined both in vitro and in vivo, leading to controversies in the
literature. We herein specifically investigated the effect of TNF-a
on the transcriptional and protein expression of the principal C-
terminus splice variants GLT-1a and GLT-1b in astrocyte
cultures. At variance with the down-regulation observed for the
GLAST, a 72 h treatment with TNF-a resulted in a substantial
increase in the mRNA expression of GLT-1a (Fig. 2C). Even
though the absolute mRNA copy number of GLT-1b appeared
considerably lower than that of GLT-1a, the expression of the
former was also robustly increased after exposure of the cultures to
Table 1. PCR primers (F : forward primer, R : reverse primer)
and size of amplicon.
Gene Sequence Amplicon (bp)
GAPDH F : 59-GTCTCCTGTGACTTCAACAG-39 76
R : 59-AGTTGTCATTGAGAGCAATGC-39
TBP F : 59-CAGGAGCCAAGAGTGAAGAAC-39 251
R : 59-AGGAAATAATTCTGGCTCATAGCTACT-39
GLT-1a F : 59-TGTCTATGCCGCACACAACT-39 90
R : 59-TCCTCAACACTGCAGTCAGC-39
GLT-1b F : 59-AATGTGTCTATGCCGCACAC-39 128
R : 59-GCAGGGGATGGTGCTTTT-39
GLAST F : 59-GGATGGAAAGATTCCAGCAA-39 128
R : 59-GCTGACGGTGAGTAGCACAA-39
doi:10.1371/journal.pone.0097649.t001
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TNF-a (Fig. 2E). The up-regulation of GLT-1 isoforms induced by
this cytokine was similar in astrocytes derived from wild-type
animals and hSOD1G93A rats (Fig. 2C & 2E). The up-regulation of
GLT-1a mRNA by TNF-a was correlated with a 2.3-fold increase
in the corresponding protein in wild-type astrocytes. In
hSOD1G93A astrocytes, the GLT-1a protein expression appeared
lower than in wild-type cells, but the relative up-regulation
observed after TNF-a treatment was similar (2.5-fold increase).
This increase did, however, not recapitulate the expression
observed in wild-type astrocytes in absence of treatment
(Fig. 2D). The level of GLT-1b protein was similar in cultures
from both genotypes and showed a comparable up-regulation after
TNF-a treatment (3.5-fold increase), in correlation with the
regulation of GLT-1b mRNA (Fig. 2F).
Effect of an Inhibition of Protein Synthesis on the
Expression of Glutamate Transporters
The above detailed data suggest that TNF-a could affect the
GLT-1 protein turnover in wild-type and hSOD1G93A astrocytes.
To further characterize the influence of TNF-a on the synthesis
and stability of GLT-1 in cultured cortical astrocytes, experiments
were repeated using cycloheximide (10 mg/ml), an inhibitor of the
protein synthesis (Fig. 3). Considering the potential toxicity of this
inhibitor, cell treatments with TNF-a were limited to 48 h, which
is sufficient to trigger the regulation of both GLAST and GLT-1
isoforms. Per se, cycloheximide did not induce any modifications
of the GLAST, but was found to totally abolish the down-
regulation observed with TNF-a (Fig. 3B), both in wild-type and
hSOD1G93A astrocytes. Similarly, expression of the GLT-1a and
GLT-1b proteins were not significantly changed after treatment
with cycloheximide in astrocytes from both genotypes, but the up-
regulation of these isoforms after TNF-a treatment was also totally
abolished in the presence of cycloheximide (Fig. 3C & 3D).
Furthermore, it appeared that these observations are not due to a
decreased expression of the TNF-a receptor 1 (TNFR1) caused by
cycloheximide as this receptor expression remained unchanged by
Western blotting after an 8h exposure to the drug (data not
shown).
Regulation of Glutamate Transporter Activity by TNF-a
The overall aspartate uptake measured on cultures from wild-
type astrocytes revealed that the treatment with TNF-a caused a
modest increase in the glutamate transporter activity which,
however, did not reach statistical significance. The transport
activity in cultures from hSOD1G93A astrocytes was slightly lower
as compared to wild-type, but more obvious was the absence of
TNF-a influence on these cells. Thus, in TNF-a-treated cultures,
the uptake measured on hSOD1G93A astrocytes was significantly
lower than on wild-type astrocytes (Fig. 4A). The nature of the
glutamate transporters supporting this uptake and its regulation
was examined using the selective pharmacological inhibitors
WAY-213613 (GLT-1) and UCPH-101 (GLAST). As summarized
in Fig. 4C, GLAST weakly contributed to the aspartate uptake in
these conditions and most of the uptake was indeed depending on
GLT-1 (Fig. 4B). Also, the GLT-1-dependent uptake was slightly
increased in wild-type astrocytes treated with TNF-a while such
regulation was not observed in hSOD1G93A astrocytes.
Discussion
Decreased glutamate uptake and neuroinflammation are well-
documented features of several neurodegenerative disorders,
including ALS [22]. While these pathological mechanisms are
frequently considered independently, it is suggested that altered
glutamate handling by astrocytes could result from local inflam-
mation [15]. Indeed, regulation of glutamate transporters by pro-
inflammatory cytokines was already reported in vitro and in vivo
in models of nervous diseases. The present data clearly indicate
that TNF-a induces a decrease in GLAST and an increase in
GLT-1a and GLT-1b expression in cortical astroglial cultures.
The down-regulation of GLAST expression in response to
inflammation was already evidenced in astrocytes and TNF-a
was identified as a key mediator of this decrease [23,24]. A
transcriptional regulation through AP-1 (activator protein 1) or
CREB (cAMP response binding protein) has been proposed as a
potential mechanism [25,26]. In accordance with data from the
literature indicating that GLAST is unaffected during ALS, the
expression of this transporter appeared similar in astrocytes from
hSOD1G93A and wild-type rats. However, considering the
evidence for a down-regulation of GLAST in astrocytes exposed
to an inflammatory environment and the robust inflammatory
response that develops in the spinal cord from ALS rats, it is
surprising that the GLAST expression remains unchanged in the
spinal cord during the disease progression. While the present study
focused on TNF-a, other cytokines and other mechanisms of
regulation could likely contribute to the progression of the disease
and may have complex effects on this transporter. Also, one
cannot exclude that astrocytes derived from the spinal cord could
show distinct responses to inflammation. It is also worth
mentioning that although GLAST mRNA is abundantly ex-
pressed, the contribution of this transporter in the total uptake
activity was found to be low. This finding obtained in mature
Figure 1. rSOD1 and hSOD1 protein expression in primary
astrocytes cultures, lumbar spinal cord and cortex from wild-
type and hSOD1G93A rats. (A) Expression of the endogenous rSOD1
(around 17 kDa) and the exogenous hSOD1 (around 19 kDa) deter-
mined by Western blotting in wild-type or hSOD1G93A astrocytes
(samples from 3 different cultures are shown). The close molecular
weight between the two SOD1 forms impairs clear-cut discrimination of
rSOD1 when hSOD1 is expressed. Expression of the rSOD1 and hSOD1
proteins examined in the lumbar spinal cord (B) and cortex (C) from
hSOD1G93A rats at various stages of the disease (P5, P60, P120, P150 and
P195) or from wild-type rats at P150. Immunoblots shown are
representative of three independent experiments.
doi:10.1371/journal.pone.0097649.g001
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astrocytes is consistent with the common view on GLT-1 as the
predominant glutamate transporter in the adult central nervous
system [27].
At variance with GLAST, the influence of an inflammatory
environment on GLT-1 remains controversial. In accordance with
the present study, several publications report on the up-regulation
Figure 2. Influence of TNF-a on GLAST, GLT-1a and GLT-1b mRNAs and proteins in cortical astrocytes from wild-type or hSOD1G93A
rats. Expression of GLAST (A), GLT-1a (C) and GLT-1b (E) mRNAs as number of copies per microgram of RNA was estimated by RT-qPCR in control
conditions or after 72 h exposure to TNF-a (20 ng/mL) using the corresponding cloned cDNA sequences as standards. Data shown are means with
SEM conducted from six independent experiments performed in duplicate. Expression of GLAST (B), GLT-1a (D) and GLT-1b (F) proteins was examined
in cells maintained in control conditions or treated with TNF-a (20 ng/mL) for 72 h. Immunoblots shown are representative of six independent
experiments. Data indicate the levels of the protein of interest normalized to GAPDH and represents means with SEM. *p,0.05 for comparison
between the same genotype.
doi:10.1371/journal.pone.0097649.g002
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of GLT-1 expression in astrocytes after exposure to pro-
inflammatory mediators. We previously found that conditioned
medium from LPS-activated microglia induces increased GLT-1
expression and activity [28]. However, others have described a
down-regulation of GLT-1 by inflammatory mediators. For
instance, a role was assigned to TNF-a during the hypoxia-
mediated suppression of GLT-1 in astrocytes [29]. These
inconsistencies may originate from the diversity of models,
pathologies and culture methods tested (e.g. duration, concentra-
tion), which may influence the TNF-a-associated signaling
pathways. Indeed, during neuroinflammation, TNF-a is described
with a Janus-face [30,31] depending on the receptor subtype
(TNFR1 and TNFR2) activated by the cytokine and the associated
signalling. The latter involves activation of caspases or transcrip-
tion factors, including NF-kB for which different binding sites are
present on the GLT-1 promoter [32]. This transcription factor
activates or represses GLT-1 via two distinct pathways (N-Myc,
MAPK) reflecting the complexity of the regulations in function of
the model considered [33,34].
The present study conducted in astrocyte cultures also
recapitulates the different levels of expression of GLT-1a and
GLT-1b, as already described in both cell and animal models of
ALS [10,11,35]. While the distinctive role of these two isoforms
remains poorly understood, the structure of GLT-1b differs from
GLT-1a by the presence of a PDZ motive at the C-terminus
domain. This additional motive could support the interaction with
some scaffold proteins containing a PDZ domain implicated in the
trafficking such as PSD-95 and PICK1 that could also ensure a
chaperone role [36–38]. Alterations in GLT-1 protein expression
are abundantly described in ALS patients and in animal models of
the disease [6,39] and a link with neuroinflammation has been
proposed [15]. While the present data highlight the potential
benefits operated by TNF-a against glutamate-mediated excito-
toxicity, one may also predict that the up-regulation of GLT-1
Figure 3. Effect of protein synthesis inhibition on the protein expression of GLAST, GLT-1a and GLT-1b on wild-type or hSOD1G93A
astrocytes. (A) Protein expression of GLAST, GLT-1a and GLT-1b was examined by immunoblotting in astrocytes from wild-type and hSOD1G93A
maintained in culture either in control conditions or treated with TNF-a (20 ng/mL) and/or using the inhibitor of protein synthesis cycloheximide
(10 mg/mL) for 48 h. Immunoblots shown are representative of four independent experiments. Data obtained after densitometric analyses of GLAST
(B), GLT-1a (C) and GLT-1b (D) proteins are means with SEM normalized to GAPDH and expressed in percent of the signal obtained for wild-type
astrocytes cultured in control conditions. * p,0.05 and *** p,0.001 for comparison between the same genotype after a different treatment and
##p,0.01 for comparison between different genotypes with the same treatment (two way ANOVA followed by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0097649.g003
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preserved in hSOD1G93A astrocytes would remain insufficient to
compensate for the loss of glutamate uptake capacity that develops
during the disease. This reinforces the concept that inflammatory
reactions, although they can induce beneficial responses in
neurodegenerative diseases, do not necessarily prevent excitotox-
icity [40,41]. It has even been proposed that TNF-a may induce
an exacerbation of glutamate-mediated excitotoxicity in a model
of ALS [42].
Prolonged exposure to cycloheximide did not change the
protein levels of GLAST and GLT-1 isoforms in astrocytes, thus
providing evidence for the rather long half-life of these astrocytic
proteins, as previously observed [43]. Furthermore, no difference
was observed between cultures from wild-type or transgenic rats,
arguing against the hypothesis for an altered stability of these
transporters in astrocytes expressing the fALS associated mutant
form of SOD1. Nevertheless, a major finding of the present study
was the loss of regulation of transporters by TNF-a when protein
synthesis is inhibited, which indicates that the opposite regulations
of GLAST and GLT-1 by TNF-a cannot be exclusively assigned
to a down-regulation of protein synthesis or to modifications in the
mRNA expression. These observations suggest that TNF-a might
generate post-translational modifications or accelerate degradation
of other proteins necessary for the regulation process of the
transporters. We, thus, hypothesize that inhibition of the protein
synthesis by cycloheximide inhibits the turnover of such partner
proteins supporting the opposite regulations of GLAST and GLT-
1.
In addition, the cytokine positively modulated the D-[3H]-
aspartate uptake in wild-type astrocytes but the amplitude of the
response appeared rather modest with respect to the robust
increase in GLT-1 expression. Besides, the uptake activity is
altered in non-treated hSOD1G93A astrocytes, but the positive
effect of TNF-a is clearly lost in this ALS model. The up-
regulation of glutamate transporters expression in astrocytes could
therefore reflect an adaptive mechanism that allows the adjust-
ment of glutamate uptake by facilitating a more rapid turnover
and trafficking of these transporters [44]. The lack of correlation
between changes in the expression of glutamate transporters and
the glutamate uptake/clearance has already been reported and
further studies are required to explain such discrepancy.
Taken together, these data highlight an opposite regulation of
GLAST and GLT-1 in cultured astrocytes when exposed to a
potent pro-inflammatory stimulus. The experimental setup only
allowed to study the consequences of short-term responses to
inflammation in isolated astrocytes, a model that certainly differs
from the sustained inflammation that can be observed in the
complex environment of the nervous parenchyma. However, our
data shed light on the putative contribution of neuroinflammation
on the regulation of glutamate transporters that may operate in the
course of neurodegenerative diseases. The intracellular pathways
supporting these regulations remain largely unknown, including
for individual isoforms of GLT-1. Nevertheless, the existence of
distinct regulatory profiles for these isoforms further suggests the
specialized role of these isoforms in physiological and pathological
conditions. A better understanding of these mechanisms could
provide some clues when attempting to manipulate these
glutamate transporters to reduce excitotoxicity in neurodegener-
ative disorders.
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Figure 4. Influence of TNF-a on the activity of glutamate transporters from wild-type or hSOD1G93A cortical astrocytes. Glutamate
transporter activity was evaluated by measuring velocity of D-[3H]-aspartate uptake (50 nmol/L) in wild-type and hSOD1G93A astrocytes treated or not
with TNF-a (20 ng/mL) for 72 h. (A) shows total uptake while (B) and (C) illustrate GLT-1- and GLAST-dependent uptake, respectively evaluated in
presence of the selective inhibitors WAY-213613 (100 mmol/L) and UCPH-101 (10 mmol/L). Shown are mean with SEM from five independent
experiments realized in quintuplicate. #p,0.05 and ###p,0.001 for comparison between different genotypes with the same treatment.
doi:10.1371/journal.pone.0097649.g004
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